Darolutamide + Goserelin
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Salivary Gland Cancer
Conditions
Salivary Gland Cancer
Trial Timeline
Apr 17, 2020 → Mar 1, 2026
NCT ID
NCT05694819About Darolutamide + Goserelin
Darolutamide + Goserelin is a phase 2 stage product being developed by Bayer for Salivary Gland Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05694819. Target conditions include Salivary Gland Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05694819 | Phase 2 | Active |
Competing Products
11 competing products in Salivary Gland Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Gefitinib | AstraZeneca | Phase 2 | 52 |
| Goserelin Acetate + Pembrolizumab | Merck | Phase 2 | 52 |
| Dovitinib | Novartis | Phase 2 | 52 |
| Sacituzumab govitecan | Gilead Sciences | Phase 2 | 51 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Ivonescimab | Summit Therapeutics | Phase 2 | 49 |
| Cabozantinib | Ipsen | Phase 2 | 49 |
| AVA6000 | Avacta Group | Phase 1 | 25 |